ClinicalTrials.gg
RecruitingNCT06719739Updated Apr 8, 2026

Functional IOL Implantation in Patients With Epiretinal Membrane

An interventional study of Intraocular lens implantation in Cataract, Intraocular Lens Complication and Epiretinal Membrane, sponsored by Eye & ENT Hospital of Fudan University. Recruiting at 2 sites in China. Open to participants aged 20 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Eye & ENT Hospital of Fudan University · Not applicable, Interventional, and Screening

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
20 Years to 90 Years
Sex
All
01

Study summary

We have designed this prospective study to evaluate macular involvement and epiretinal membrane (ERM) grading by OCT in eyes with ERM and to compare clinical outcomes after implantation of Enhance IOL with standard monofocal IOL in eyes with ERM grading preoperatively, aiming to find out whether functional IOL is benefit for patients with ERM.

Read the detailed description

This study is a prospective, multicenter, comparative study. Cataract patients scheduled for surgery will be evaluated by OCT, and those diagnosed with grade-1 macular epiretinal membrane will be implanted in different IOLs according to the patients' decision: monofocal IOL or functional IOL. The follow-up duration sets to be 2-years. Outcome measures: The primary outcome measure is visual acuity measured according to UDVA and CDVA at 5 m; UIVA at 66 cm; and UNVA at 40 cm. Visual examination will be performed twice under sufficient lighting, and the international standard visual acuity table will be used. The secondary outcome measures are as follows: (1) OCT examination and Amsler grid test. (2) HOA such as coma, spherical, trefoil, and secondary astigmatism will be measured using internal and total values at a 3-mm pupil size with the HOYA iTrace ray-tracing system (Tracey Technologies, Houston, TX, USA); (3) Modulation transfer function (MTF) curve and Strehl ratio (SR) will be also measured using internal and total values at a 3-mm pupil size with the HOYA iTrace ray-tracing system; (4) Defocus curves for each IOL will be obtained by plotting the mean visual acuity with 13 values of defocus from +2.0 D to -4.0 D on the ETDRS chart in logMAR units. The defocus curve simulates the patient's visual acuity at different distances by placing positive and negative lenses in 0.5 D increments in front of the patient's eyes. The measurements will be performed by adding lenses to CDVA; (5) Contrast sensitivity (CS) will be assessed with best distance correction using the Optec6500 (Stereo Optical Co., Inc., Chicago, IL, USA). Assessments will be made at spatial frequencies of 1.5, 3, 6, 12, and 18 cycles per degree (cpd), with or without glare, under photopic or mesopic conditions (background luminance of 85 cd/m2 or 3 cd/m2). CS value refers to the value of the last patch that can be recognized, and all patients will see at least one patch. All CS data will be transformed to logarithmic units and log CS values for analysis; (6) Reading ability will be measured by the Chinese Reading Visual Acuity Chart (CRVAC) at near and intermediate distances. With the CRVAC, reading acuity (in logMAR) and reading speed (in words per minute) can be measured at a predetermined or preferred distance successively. The minimum distinguishable font size and corresponding visual acuity of the patients with UNVA and UIVA above 0.1 LogMAR will be respectively measured at 66 cm and 40 cm under photopic conditions. The patients will be required to read a text with a font size of 5 point (LogMAR 0.5) at 40cm and of 8 point (LogMAR 0.7) at 66cm. The reading time will be timed and converted to words per minute; and (7) the functional vision and incidence of photic phenomena will be surveyed using VF-14 questionnaire and Qov questionnaire which are attached in the supplementary materials. Study population >90 subjects/ 90 eyes (45 eyes per group, total 2 groups) Primary/Secondary endpoints (or perhaps exploratory endpoint) The primary endpoint of this study is to demonstrate the noninferiority of functional IOL group to monodical IOL group in mean CDVA and UDVA (5m) postoperatively. If the primary endpoint is met, the first secondary endpoint is to demonstrate superiority of ICB00 group to DCB00 group in mean UIVA (66cm) and UNVA (40cm). The prespecified Snellen equivalent targets of ICB00 group are determined and included the following: 20/25 or better photopic UIVA (measured at 66 cm); 20/40 (0.5 decimal) or better photopic UNVA at 40 cm. Additional secondary endpoints are to compare the defocus curve behaviour, objective visual quality, reading ability and subject satisfaction between the two groups. Study Timeline Visit Schedule

1.Baseline visit 2.2. 1-day visit 3.3. 1-week visit 4.4. 1-month visit 5.5. 3-month visit 6.6. 6-month visit 7.7. 1-year visit 8.8. 2-year visit

02

Conditions studied

  • Cataract
  • Intraocular Lens Complication
  • Epiretinal Membrane
03

In context

Cataract

1,629 studies on the registry are indexed under Cataract; 235 are open to participants now.

This study's planned enrollment of 90 is above the median of 79 across 1,092 interventional studies indexed under Cataract.

Browse Cataract studies →

Lead sponsor

Eye & ENT Hospital of Fudan University is the lead sponsor of 126 studies on the registry; 70 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Requirement for cataract extraction
  • Age > 40 years
  • Axial length in 21mm to 25mm
  • ERM

Exclusion criteria

Exclusion Criteria:

  • Residual corneal astigmatism > 1.0 D
  • Amblyopia
  • Previous ocular surgery
  • Other ocular pathologies apart from mERM, such as diabetic retinopathy, macular degeneration, glaucoma with field defects
  • Requirements for further ocular surgery (other than Nd:YAG capsulotomy) or retinal laser treatments during the study
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Functional IOL

    Experimental group

    Device: Intraocular lens implantation

  • Other
    Monofocal IOL

    Control Group

    Device: Intraocular lens implantation

Interventions

  • DeviceIntraocular lens implantation

    Cataract patients scheduled for surgery will be evaluated by OCT, and those diagnosed with macular epiretinal membrane will be implanted in different IOLs according to the patients' decision: monodical IOL or functional IOL.

06

What researchers measure

Primary outcomes

  1. UDVA

    Uncorrected distance visual acuity

    Time frame: 1-day/1-week/1-month/3-months/6-monhts/1-year/2-years

07

Study locations

2 of 2 sites recruiting
  • Eye and Ear, Nose, and Throat Hospital of Fudan University
    Shanghai, Shanghai Municipality 200031, China
    Recruiting
  • Shanghai Heping Eye Hospital
    Shanghai, Shanghai Municipality 200081, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Sep 2026, 24 months after the start.

Of 300 non-industry interventional studies with no phase under Cataract, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 24 months is above that.

Counting every sponsor, half of 490 studies reached it within 17 months; a quarter within 9 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2024
First posted
Dec 6, 2024
StartActual
Sep 21, 2024
Primary completionEst.
Sep 21, 2026
CompletionEst.
Sep 21, 2026
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06719739
Responsible party
Jin Yang (Professor, Eye & ENT Hospital of Fudan University) — Principal investigator
First posted
Dec 6, 2024
Start date
Sep 21, 2024
Primary completion
Sep 21, 2026 (estimated)
Completion
Sep 21, 2026 (estimated)
Last update
Apr 8, 2026

Study contacts

Jin Yang
Contact
jin_er76@hotmail.com
13671632525

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion